Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia
ConclusionFindings in Japanese patients are consistent with those of the overall ADMIRAL study population.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Anemia | Cancer & Oncology | Chemotherapy | Hematology | Japan Health | Leukemia | Study